Clinical Trials in Progress

About the Program

Clinical Trials in Progress sessions are designed to increase awareness of important clinical trials that are either ongoing or in the late design phase. These trials should not be completed and there is no expectation that data will be presented. Accepted abstracts will describe studies that are expected to substantially influence practice when they are ultimately reported and/or published.

Trials that are accepted will be featured in the Learning Lab, which showcases engaging presentations at AUA2026. This venue will be adjacent to the Science & Technology Hall and attracts a robust attendance.

Apply Now

Eligible Studies

Investigators can present ongoing industry-sponsored or investigator-initiated independent studies that are about to open, currently accruing participants, or in follow-up. Submissions should describe the trial's purpose, design and eligibility criteria, but have not reported primary findings. There is no expectation that preliminary data will be presented.

Submission Guidelines

The content should be organized into two sections:

Background

• Scientific rationale for the trial
• Brief description of interventions
• Correlative studies of particular interest

Methods

• Trial design and statistical methods, highlighting any new features
• Treatment or interventions planned
• Major eligibility criteria, highlighting any unusual aspects
• Current enrollment status, without providing results or endpoints
• Phase II and III studies must state how many patients have been enrolled out of the planned total
• Phase III trials may state when the data monitoring committee last reviewed the trial and what it recommended

Submissions must also include the following:

• Title (limited to 255 characters, spaces included)
• Author information
• Clinical trial registry number
• Funding

Do not include the following information:

• Preliminary data or results
• Proprietary drug names or the names of drug manufacturers. If necessary, the proprietary drug name may be included in parentheses directly after the generic name on first use
• Information about pricing, fees, or reimbursement related to trial participation

Prior Presentation or Publication

• Prior to the AUA Annual Meeting, the contents of the submission must not have been presented at or published in conjunction with any scientific, medical, or educational meeting with the following exceptions:
  • Abstracts previously accepted to AUA Sectional meetings or select urologic sub-specialty societies are eligible for submission even if presented or published under the scientific, medical, or educational outlets of those meetings. Authors are strongly encouraged to provide updated data in the abstract submitted to the AUA Annual Meeting.
  • Study results may be presented at closed (non-public) meetings on the condition that no meeting materials are publicly disseminated in any format.
• Additionally, the contents and conclusions must not be published as a full-length research article in a scientific, medical, or educational publication (in any medium), in whole or in part, before the article is published online by the AUA. Full-length pre-prints (non-peer-reviewed research articles published online for public dissemination and public comments are permitted before the abstract is submitted.

Restrictions on the Use of Artificial Intelligence

• Authors must refrain from using, sharing or uploading content accessed through AUA websites or educational activities into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
• Authors must refrain from using, or sharing any AUA content/data to train, alter, inform, or otherwise affect any form of artificial intelligence; deep learning; machine learning; similar automated, autonomous, self-improving, or otherwise adaptive software model or program (whether automated as a whole or in part).

Additional Guidance

• Figures, graphs, images, and/or other file attachments may not be included with the submission.
• After the submission deadline, revisions to the content, including authorship, will not be accepted. It is the responsibility of the authors to ensure the submission is complete and free of spelling, grammatical and scientific errors.
• The Program Committee has the authority to reject submissions that are incomplete, deemed purely for marketing purposes, duplicate submissions by the same authors and based on the same study population or data, not written in English, or in violation of the policies outlined above.
• Requests to withdraw a submission may be sent to speakers@AUAnet.org.

Review Criteria

Submissions will be evaluated on the following criteria:

• Strength of Science – Does the trial address an important and new question?
• Trial Design – Are the eligibility criteria, study endpoints, and planned analysis well-defined?
• Collaboration – Is there potential for investigator collaboration?
• Relevance – Will the results be relevant and of interest to the AUA Annual Meeting community?

The outcome will be communicated to the principal investigator via email, who is responsible for notifying any co-authors of the decision.

Trials Accepted for Presentation

Registration Requirement

• The principal investigator/presenter must attend the 2026 AUA Annual Meeting in Washington, DC. The presenting author is required to respond to the invitation to present by the date indicated in the acceptance letter. Failure to register by this date will forfeit the opportunity to present and the trial will be withdrawn from publication in The Journal of Urology^®.
• The presenter is responsible for any expenses associated with the preparation, submission and presentation of the abstract. Registration fee waivers and travel grants are not available for presenters.

Presentation

• Clinical Trials in Progress accepted for presentation will be scheduled in the Learning Lab according to topic category. The principal investigator will have approximately 10 minutes to present and take questions from the audience.
• At the time of acceptance notification, details will be communicated regarding the date and time of presentation along with guidance and expectations.

Publication

• Abstracts accepted for the Annual Meeting are copyrighted by the American Urological Association and published in a supplement of The Journal of Urology^® on the first day of the Annual Meeting. No part of materials published in The Journal of Urology^® may be reproduced without written permission of the publisher. For information on requesting permission to reuse The Journal of Urology^®, visit shop.lww.com/journal-permission or contact publications@AUAnet.org.

Embargo

Please follow this link to view the embargo policy.

Apply Now

Contact

Questions regarding the submission process may be sent to the annual meeting programs team at speakers@AUAnet.org.